Company
ASX:MSB / NASDAQ:MESO
First FDA-approved MSC product (Ryoncil).
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:MSB / NASDAQ:MESO |
| Secondary listing | NASDAQ |
| Market cap | ~A$2.6–2.8B |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
Recent inflection
Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD; Ryoncil Y1 revenue ~US$100M.
Keep reading
Sources
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.